首页> 外文期刊>Risk Management and Healthcare Policy >Current Options in the Treatment of COVID-19: A Review
【24h】

Current Options in the Treatment of COVID-19: A Review

机译:Covid-19治疗中的当前选择:审查

获取原文
           

摘要

Novel Coronavirus, also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in December 2019 in China and spread rapidly all around the world infecting many people. To date, no specific vaccines and drugs have been developed for this disease. Also, due to the COVID-19 pandemic and high prevalence of the infected patients, the drugs and the therapies of other past viral epidemics have been used for this disease. Many studies have been performed on the specific treatments to find whether or not they are effective on COVID-19 patients. In this review, we collected information about the most widely used drugs to treat COVID-19 (coronavirus disease 2019) belonging to groups of antivirals, antibiotics, immune modulators, and anticoagulants. Some of these compounds and drugs were used directly by inpatients, so researchers have examined others in laboratory conditions. This study considered the pros and cons of using these treatments separately and together and compared their results. By studying this review, we hope to provide useful information for researchers.
机译:新型冠状病毒,也称为严重急性呼吸综合征Coronavirus 2(SARS-COV-2),于2019年12月在中国出现,并迅速传播世界各地的许多人。迄今为止,没有为这种疾病开发特异性疫苗和药物。此外,由于Covid-19感染患者的大流行和高患病率,药物和其他过去病毒流行病的治疗已被用于这种疾病。对特定治疗进行了许多研究,以查找它们是否对Covid-19患者有效。在这篇综述中,我们收集了有关抗病毒,抗生素,免疫调节剂和抗凝血剂组的Covid-19(冠状病毒疾病2019)的含有最广泛使用的药物的信息。其中一些化合物和药物直接通过住院性使用,因此研究人员在实验室条件下检查了他人。本研究审议了单独使用这些治疗的优缺点,并将其结果进行了比较。通过研究审查,我们希望为研究人员提供有用的信息。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号